Fighting Bax: Towards a Parkinson's disease therapy

Trends in Neurosciences

Volumn 24, Issue 5, 2001, Pages 255-

  Ploix, Corinne ^a   Spier, Avron D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NEUROTOXIN; PROTEIN BCL 2;

AKINESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL DEATH; CELL SURVIVAL; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; MOUSE; MUSCLE TUMOR; NERVE DEGENERATION; NERVE ENDING; NEUROTOXICITY; NONHUMAN; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 0035341337     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(00)01837-3     Document Type: Short Survey

References (1)

1. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease